Active, not recruitingPhase 2NCT03876769
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- CTL019(biological)
- Enrollment
- 121 enrolled
- Eligibility
- 1-25 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- Children s Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- City of Hope National Medical, Duarte, California, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Mattel Childrens Hospital UCLA, Los Angeles, California, United States
- Childrens Hospital of Orange County, Orange, California, United States
- Rady Children s Hospital, San Diego, California, United States
- UCSF Medical Center, San Francisco, California, United States
- Stanford University Medical Center, Stanford, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Childrens National Hospital, Washington D.C., District of Columbia, United States
- Johns Hopkins All Childrens, St. Petersburg, Florida, United States
- Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
- James Whitcomb Riley Hospital For Children, Indianapolis, Indiana, United States
- Johns Hopkins Oncology Center, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Children's Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03876769 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University